AKT1 and cancer: The inhibition of FGF19, achieved through methods such as siRNA-mediated silencing or neutralization by an anti-FGF19 antibody, specifically decreases AKT phosphorylation, suppresses cancer cell growth, and enhances doxorubicin sensitivity in FGFR4+/FGF19+ BC cells 46.